Cargando…

Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice

Human immunodeficiency virus (HIV) induced AIDS causes a large number of infections and deaths worldwide every year, still no vaccines are available to prevent infection. Recombinant herpes simplex virus type 1 (HSV-1) vector-based vaccines coding the target proteins of other pathogens have been wid...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Beibei, Mao, Hongyan, Zhu, Hongjuan, Guo, Jingxia, Zhou, Paul, Ma, Zhenghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063819/
https://www.ncbi.nlm.nih.gov/pubmed/37007461
http://dx.doi.org/10.3389/fmicb.2023.1136664
_version_ 1785017776131276800
author Zhang, Beibei
Mao, Hongyan
Zhu, Hongjuan
Guo, Jingxia
Zhou, Paul
Ma, Zhenghai
author_facet Zhang, Beibei
Mao, Hongyan
Zhu, Hongjuan
Guo, Jingxia
Zhou, Paul
Ma, Zhenghai
author_sort Zhang, Beibei
collection PubMed
description Human immunodeficiency virus (HIV) induced AIDS causes a large number of infections and deaths worldwide every year, still no vaccines are available to prevent infection. Recombinant herpes simplex virus type 1 (HSV-1) vector-based vaccines coding the target proteins of other pathogens have been widely used for disease control. Here, a recombinant virus with HIV-1 gp160 gene integration into the internal reverse (IR) region-deleted HSV-1 vector (HSV-BAC), was obtained by bacterial artificial chromosome (BAC) technology, and its immunogenicity investigated in BALB/c mice. The result showed similar replication ability of the HSV-BAC-based recombinant virus and wild type. Furthermore, humoral and cellular immune response showed superiority of intraperitoneal (IP) administration, compared to intranasally (IN), subcutaneous (SC) and intramuscularly (IM), that evidenced by production of significant antibody and T cell responses. More importantly, in a prime-boost combination study murine model, the recombinant viruses prime followed by HIV-1 VLP boost induced stronger and broader immune responses than single virus or protein vaccination in a similar vaccination regimen. Antibody production was sufficient with huge potential for viral clearance, along with efficient T-cell activation, which were evaluated by the enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FC). Overall, these findings expose the value of combining different vaccine vectors and modalities to improve immunogenicity and breadth against different HIV-1 antigens.
format Online
Article
Text
id pubmed-10063819
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100638192023-04-01 Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice Zhang, Beibei Mao, Hongyan Zhu, Hongjuan Guo, Jingxia Zhou, Paul Ma, Zhenghai Front Microbiol Microbiology Human immunodeficiency virus (HIV) induced AIDS causes a large number of infections and deaths worldwide every year, still no vaccines are available to prevent infection. Recombinant herpes simplex virus type 1 (HSV-1) vector-based vaccines coding the target proteins of other pathogens have been widely used for disease control. Here, a recombinant virus with HIV-1 gp160 gene integration into the internal reverse (IR) region-deleted HSV-1 vector (HSV-BAC), was obtained by bacterial artificial chromosome (BAC) technology, and its immunogenicity investigated in BALB/c mice. The result showed similar replication ability of the HSV-BAC-based recombinant virus and wild type. Furthermore, humoral and cellular immune response showed superiority of intraperitoneal (IP) administration, compared to intranasally (IN), subcutaneous (SC) and intramuscularly (IM), that evidenced by production of significant antibody and T cell responses. More importantly, in a prime-boost combination study murine model, the recombinant viruses prime followed by HIV-1 VLP boost induced stronger and broader immune responses than single virus or protein vaccination in a similar vaccination regimen. Antibody production was sufficient with huge potential for viral clearance, along with efficient T-cell activation, which were evaluated by the enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FC). Overall, these findings expose the value of combining different vaccine vectors and modalities to improve immunogenicity and breadth against different HIV-1 antigens. Frontiers Media S.A. 2023-03-17 /pmc/articles/PMC10063819/ /pubmed/37007461 http://dx.doi.org/10.3389/fmicb.2023.1136664 Text en Copyright © 2023 Zhang, Mao, Zhu, Guo, Zhou and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Zhang, Beibei
Mao, Hongyan
Zhu, Hongjuan
Guo, Jingxia
Zhou, Paul
Ma, Zhenghai
Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
title Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
title_full Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
title_fullStr Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
title_full_unstemmed Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
title_short Response to HIV-1 gp160-carrying recombinant virus HSV-1 and HIV-1 VLP combined vaccine in BALB/c mice
title_sort response to hiv-1 gp160-carrying recombinant virus hsv-1 and hiv-1 vlp combined vaccine in balb/c mice
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063819/
https://www.ncbi.nlm.nih.gov/pubmed/37007461
http://dx.doi.org/10.3389/fmicb.2023.1136664
work_keys_str_mv AT zhangbeibei responsetohiv1gp160carryingrecombinantvirushsv1andhiv1vlpcombinedvaccineinbalbcmice
AT maohongyan responsetohiv1gp160carryingrecombinantvirushsv1andhiv1vlpcombinedvaccineinbalbcmice
AT zhuhongjuan responsetohiv1gp160carryingrecombinantvirushsv1andhiv1vlpcombinedvaccineinbalbcmice
AT guojingxia responsetohiv1gp160carryingrecombinantvirushsv1andhiv1vlpcombinedvaccineinbalbcmice
AT zhoupaul responsetohiv1gp160carryingrecombinantvirushsv1andhiv1vlpcombinedvaccineinbalbcmice
AT mazhenghai responsetohiv1gp160carryingrecombinantvirushsv1andhiv1vlpcombinedvaccineinbalbcmice